EverSource Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.85M Sell
7,378
-2,242
-23% -$2.29M 0.3% 73
2026
Q1
$8.85M Buy
9,620
+2,491
+35% +$2.53M 0.27% 74
2025
Q4
$7.66M Buy
7,129
+733
+11% +$701K 0.28% 78
2025
Q3
$4.88M Buy
6,396
+276
+5% +$205K 0.19% 104
2025
Q2
$4.77M Buy
6,120
+1,078
+21% +$838K 0.22% 100
2025
Q1
$4.16M Buy
5,042
+999
+25% +$831K 0.23% 94
2024
Q4
$3.12M Buy
4,043
+248
+7% +$205K 0.18% 113
2024
Q3
$3.36M Buy
3,795
+177
+5% +$159K 0.21% 100
2024
Q2
$2.91M Buy
3,618
+109
+3% +$87.2K 0.19% 106
2024
Q1
$2.74M Buy
3,509
+420
+14% +$299K 0.22% 100
2023
Q4
$1.8M Sell
3,089
-43
-1% -$25.1K 0.17% 116
2023
Q3
$1.68M Sell
3,132
-64
-2% -$33K 0.18% 118
2023
Q2
$1.5M Sell
3,196
-287
-8% -$120K 0.17% 121
2023
Q1
$1.2M Buy
3,483
+12
+0.3% +$4.05K 0.15% 126
2022
Q4
$1.27M Sell
3,471
-208
-6% -$73.7K 0.19% 99
2022
Q3
$1.19M Sell
3,679
-60
-2% -$19K 0.27% 69
2022
Q2
$1.21M Buy
3,739
+354
+10% +$106K 0.31% 57
2022
Q1
$970K Buy
3,385
+974
+40% +$251K 0.25% 75
2021
Q4
$667K Buy
+2,411
New +$611K 0.19% 95

Other funds holding LLY

EverSource Wealth Advisors's LLY Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Eli Lilly (LLY) stake by 23% in Q2 2026, selling an estimated $2.29M and leaving 7,378 shares worth $8.85M. The position accounts for 0.3% of the portfolio, ranked #73.

EverSource Wealth Advisors first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • EverSource Wealth Advisors held 7,378 shares of Eli Lilly worth $8.85M as of Q2 2026.
  • EverSource Wealth Advisors sold 2,242 Eli Lilly shares in Q2 2026, an estimated $2.29M.
  • Eli Lilly made up 0.3% of EverSource Wealth Advisors's portfolio in Q2 2026, its #73 holding.
  • EverSource Wealth Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.